{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477316140
| IUPAC_name = ''N''-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
| image = Agomelatine formula.svg
| image2 = Agomelatine-3D-ball.png

<!--Clinical data-->
| tradename =  维度新（Valdoxan）
| Drugs.com = {{drugs.com|international|agomelatine}}
| licence_EU = Valdoxan
| pregnancy_AU = B1
| legal_AU = S4
| legal_UK = POM
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| protein_bound = 95%<ref name = PI/>
| bioavailability = 1%<ref name=PI>{{cite web|title=VALDOXAN®   Product Information|url=https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3|work=TGA eBusiness Services|publisher=Servier Laboratories Pty Ltd|accessdate=2013-10-14|format=PDF|date=2013-09-23|archive-date=2017-03-24|archive-url=https://web.archive.org/web/20170324132859/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-07273-3|dead-url=no}}</ref>
| metabolism = 肝脏 (90% [[CYP1A2|CYP1A2]] 和10% [[CYP2C9|CYP2C9]])<ref name = PI/>
| elimination_half-life = 1-2 小时<ref name = PI/>
| excretion =  [[尿液|尿液]] (80%, 大部分是代谢产物)<ref name = PI/>

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 138112-76-2
| ATC_prefix = N06
| ATC_suffix = AX22
| PubChem = 82148
| IUPHAR_ligand = 198
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB06594
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 74141
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 137R1N49AD
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02578
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 10878

<!--Chemical data-->
| C=15 | H=17 | N=1 | O=2
| molecular_weight = 243.301 g/mol
| smiles = O=C(NCCc1c2c(ccc1)ccc(OC)c2)C
| InChI = 1/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
| InChIKey = YJYPHIXNFHFHND-UHFFFAOYAC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YJYPHIXNFHFHND-UHFFFAOYSA-N
}}

'''阿戈美拉汀（{{lang-en|Agomelatine}}）''' ，商品名为'''维度新（Valdoxan）'''，是一种[[褪黑素|褪黑素]]受体[[激动剂|激动剂]]类[[抗抑郁药|抗抑郁药]]，由法国施维雅（Servier）公司研制。阿戈美拉汀主要用来治疗[[重度抑郁症|重度抑郁症]]（MDD），并且证据指出阿戈美拉汀不会产生[[停药综合症|停药综合症]]和导致[[SSRI後的性功能障礙|性功能障碍]]（对比[[SSRI|SSRI]]、[[SNRI|SNRI]]与[[三环类抗抑郁药|三环类抗抑郁药]]）。 阿戈美拉汀对改善睡眠和认知也有积极的作用。

==结构==
[[File:Agomelatine-vs-melatonin-2D-skeletal.png|200px]](上)和阿戈美拉汀(下)的[[分子结构|分子结构]]对比]]

==引用==
{{reflist}}
{{Hypnotics and sedatives}}